The Mumbai based mid-cap pharmaceutical firm, Benzochem Lifesciences Pvt Ltd (BLPL), is set to commission its new manufacturing facility at Tarapur, with an investment of Rs 25 crore, by mid September.

According to the company, the new facility, validation of the same is in progress, will be an integrated full-fledged R&D centre dedicated for process development of anti-cancer APIs and formulations. The facility, which is claimed to be first of its kind in India, is dedicated only for anti-cancer products. It will engage in the production of anti-cancer bulk drugs with non-infringing route of synthesis and finished dosages, which do not infringe existing patents.

Talking to Pharmabiz, Kannan Vishwanath, director, Benzochem Lifesciences Pvt Ltd, said, "We are in the process of setting up an integrated full fledged R&D centre dedicated for process development of anti-cancer APIs and formulations. The facility, validation of the same is going on, will commence operation by mid September".

Benzochem, which has been registering 100 per cent growth in the consecutive years, is expecting further boost in the revenue with the commissioning of new facility. According to Vishwanath, the facility has been built as per the international standards and the company will file USDMF of two anti-cancer APIs shortly. The company is planning to dedicate 60 per cent of its volumes for regulated markets of Europe, US, Japan and Australia, he added.

It is learnt that Benzochem, which is tied up with companies like Unijules Lifesciences Ltd, Regeneix, Pharmed (Europe) Ltd and Xavier Labs, is in discussions with several overseas companies for marketing tie-up. Commenting on the development, Vishwanath, said, "We shall be tying up with companies who intend to launch anti-cancer drugs in Europe and North America." However, he refused to reveal more on the same.